Ask AI

CDH6 ADCs: Integration Into Ovarian Cancer Clinical Practice, Including Patient Selection

Video
This activity is available for 0.25 CME/CE credit(s).

Released: October 26, 2026

Expiration: April 25, 2027

See Activity Collection

Although there are no approved drugs targeting cadherin-6 (CDH6) yet, multiple agents are in clinical trials. This activity focuses on the integration, utility, and management of CDH6-directed antibody–drug conjugates (ADCs) for patients with high-grade serous ovarian cancer. Topics covered include CDH6 expression in ovarian cancer, where potential treatment sequencing can accommodate CDH6 ADCs based on available evidence, what adverse events are of greatest potential concern with CDH6-directed ADCs, and how HCPs can manage these associated adverse events.

CDH6 ADC Integration

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with ovarian cancer do you provide care for in a typical month?​

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following patients with ovarian cancer would be a candidate for a trial of a CDH6 ADC?

4.

A patient in your practice with platinum-resistant ovarian cancer is considering enrolling in a trial to receive a CDH6-targeting ADC. During your discussions with her, which of the following types of adverse events would you tell her is the most common toxicity associated with CDH6-directed ADCs that you would be monitoring for and managing as needed to make sure that she is tolerating her treatment well?